Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

Cylexin enters clinical trials in newborns

Feb. 21, 1997

Novel vasopressin antagonists from Fujisawa

Feb. 21, 1997

Biorex discloses antiischemic agents

Feb. 20, 1997

Zambon discloses ACE/NEP inhibitors

Feb. 20, 1997

Antiarrhythmic agents from Merck & Co.

Feb. 19, 1997

German launch for ACE inhibitor

Feb. 17, 1997

Approval anticipated for TMR using Heart Laser

Feb. 14, 1997

Zeneca describes ET antagonists

Feb. 14, 1997

ICOS' Hu23F2G enters phase II

Feb. 13, 1997

Novel antiarrhythmic agents described by Merck & Co.

Feb. 13, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.